Director of Business Development, PharmaIN Corp.
PharmaIN makes Peptides better! PharmaIN leverages proprietary platforms for API enhancement and delivery
PharmaIN has developed innovative technologies that make peptides safer and more effective with enhanced IP protections. Our 2 primary tools used independently or together enable us to work in collaborations with other pharma/biotech companies as well as develop our own drug products.
1) PGC – Protected Graft Co-Polymer is an excipient alternative of PEGylation for extending half-life, improving stability, and targeting of peptides.
2) PeptiLINK – peptide engineering technologies that improve safety, selective potency and patentability of peptides for proven targets.
Our primary product is in the CMC stages to prepare GMP material for clinical trials and we are building our own pipeline that leverages this work. We are also looking for partners where we can work together to quickly make their peptide APIs into viable therapies. Quickly converting a proven generic peptide IV therapy into a newly patented, effective, SQ drug is a typical example of how our half-life extension, enhanced potency and IP capabilities can bring value to our partners.
Mark Edelsward, Director of Business Development
Mark has over 20 years of experience in technology sales leadership. Prior to PharmaIN, Mark was Vice President of WW Sales and Marketing at Data I/O Corp, Director of OEM Technology Sales at Microsoft and Vice President of International Sales at Listen Inc.